3-33068245-G-T

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PS1_ModeratePM1PM2PM5PP3_ModeratePP5_Very_Strong

The NM_000404.4(GLB1):​c.442C>A​(p.Arg148Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000818 in 1,613,974 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R148C) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000083 ( 0 hom. )

Consequence

GLB1
NM_000404.4 missense

Scores

12
5
1

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:8O:1

Conservation

PhyloP100: 2.81
Variant links:
Genes affected
GLB1 (HGNC:4298): (galactosidase beta 1) This gene encodes a member of the glycosyl hydrolase 35 family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature lysosomal enzyme. This enzyme catalyzes the hydrolysis of a terminal beta-linked galactose residue from ganglioside substrates and other glycoconjugates. Mutations in this gene may result in GM1-gangliosidosis and Morquio B syndrome. [provided by RefSeq, Nov 2015]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PS1
Transcript NM_000404.4 (GLB1) is affected with MISSENSE_VARIANT having same AA change as one Pathogenic present in UniProt
PM1
In a strand (size 2) in uniprot entity BGAL_HUMAN there are 6 pathogenic changes around while only 0 benign (100%) in NM_000404.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chrnull-null-null-null is described in UniProt as null.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.923
PP5
Variant 3-33068245-G-T is Pathogenic according to our data. Variant chr3-33068245-G-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 551757.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-33068245-G-T is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GLB1NM_000404.4 linkc.442C>A p.Arg148Ser missense_variant Exon 4 of 16 ENST00000307363.10 NP_000395.3 P16278

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GLB1ENST00000307363.10 linkc.442C>A p.Arg148Ser missense_variant Exon 4 of 16 1 NM_000404.4 ENSP00000306920.4 P16278

Frequencies

GnomAD3 genomes
AF:
0.0000723
AC:
11
AN:
152130
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000162
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000361
AC:
9
AN:
249276
Hom.:
0
AF XY:
0.0000444
AC XY:
6
AN XY:
135250
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000796
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000828
AC:
121
AN:
1461726
Hom.:
0
Cov.:
31
AF XY:
0.0000770
AC XY:
56
AN XY:
727156
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000998
Gnomad4 OTH exome
AF:
0.000166
GnomAD4 genome
AF:
0.0000723
AC:
11
AN:
152248
Hom.:
0
Cov.:
32
AF XY:
0.0000537
AC XY:
4
AN XY:
74440
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000162
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000117
Hom.:
0
Bravo
AF:
0.0000529
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000367
AC:
3
ExAC
AF:
0.0000331
AC:
4
EpiCase
AF:
0.000218
EpiControl
AF:
0.000119

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:3
Jan 25, 2022
Revvity Omics, Revvity
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aug 02, 2021
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Published functional studies demonstrate R148S leads to a decrease in enzymatic activity (Zhang et al., 2000); Not observed at significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20175788, 10839995, 33240792, 16674934, 29352662, 15365997, 16763919, 25600812, 18353697, 22784478, 10841810, 24024947) -

Jan 17, 2018
Eurofins Ntd Llc (ga)
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mucopolysaccharidosis, MPS-IV-B;C0268271:Infantile GM1 gangliosidosis;C0268272:GM1 gangliosidosis type 2;C0268273:GM1 gangliosidosis type 3 Pathogenic:2
May 15, 2017
Counsyl
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Dec 23, 2023
Fulgent Genetics, Fulgent Genetics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

GLB1-related disorder Pathogenic:1
Sep 03, 2023
PreventionGenetics, part of Exact Sciences
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The GLB1 c.442C>A variant is predicted to result in the amino acid substitution p.Arg148Ser. This variant has been reported in multiple individuals with GM1 gangliosidosis (see for example, Hinek et al. 2000. PubMed ID: 10841810; Table 1, Hofer et al. 2010. PubMed ID: 20175788; Table 1, Nestrasil et al. 2017. PubMed ID: 29352662). An in vitro experimental study suggests this variant impacts protein function (Table 2, Zhang et al. 2000. PubMed ID: 10839995). This variant is reported in 0.0086% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-33109737-G-T). Additionally, two different nucleotide changes that affect the same amino acid (p.Arg148Cys and p.Arg148His) have been classified as pathogenic and likely pathogenic, respectively (Internal Data, PreventionGenetics). The p.Arg148Ser variant is interpreted as pathogenic. -

Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
May 11, 2018
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: GLB1 c.442C>A (p.Arg148Ser) results in a non-conservative amino acid change located in the Glycoside hydrolase 35 catalytic domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.3e-05 in 276992 control chromosomes (gnomAD and publications). This frequency is not significantly higher than expected for a pathogenic variant in GLB1 causing GM1 gangliosidosis (4.3e-05 vs 2.00e-03), allowing no conclusion about variant significance. The variant, c.442C>A, has been reported in the literature in several individuals affected with GM1 gangliosidosis (Zhang_2000, Hofer_2010, Nestrasil_2018). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein maturation and enzyme activity, with both being significantly reduced in the presence of the variant (Zhang_2000). Additionally, other variants at the Arg148 residue have been reported as associated with disease (p.Arg148Cys and p.Arg148His), suggesting that this codon is important for function. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. -

GM1 gangliosidosis;C0086652:Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
Nov 22, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 148 of the GLB1 protein (p.Arg148Ser). This variant is present in population databases (rs192732174, gnomAD 0.009%). This missense change has been observed in individual(s) with GM1 gangliosidosis (PMID: 10839995, 20175788, 25600812). ClinVar contains an entry for this variant (Variation ID: 551757). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt GLB1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GLB1 function (PMID: 10839995). This variant disrupts the p.Arg148 amino acid residue in GLB1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15986423, 17221873, 23151865, 25936995). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -

GM1 gangliosidosis Other:1
-
GenomeConnect - GM1
Significance: not provided
Review Status: no classification provided
Collection Method: phenotyping only

Variant interpreted as Pathogenic and reported on 09-25-2014 by Lab or GTR ID 239772. GenomeConnect-GM1 assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.99
BayesDel_addAF
Pathogenic
0.41
D
BayesDel_noAF
Pathogenic
0.55
CADD
Pathogenic
27
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.88
.;.;D
Eigen
Pathogenic
0.81
Eigen_PC
Pathogenic
0.68
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Pathogenic
0.97
.;.;D
M_CAP
Pathogenic
0.79
D
MetaRNN
Pathogenic
0.92
D;D;D
MetaSVM
Pathogenic
0.99
D
PrimateAI
Uncertain
0.59
T
PROVEAN
Pathogenic
-4.7
D;D;D
REVEL
Pathogenic
0.95
Sift
Uncertain
0.020
D;D;D
Sift4G
Uncertain
0.044
D;D;D
Vest4
0.95
MVP
0.98
MPC
0.92
ClinPred
0.99
D
GERP RS
5.3
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
gMVP
0.99

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs192732174; hg19: chr3-33109737; COSMIC: COSV100256712; COSMIC: COSV100256712; API